Industry
Biotechnology
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Loading...
Open
3.28
Mkt cap
18M
Volume
16K
High
3.45
P/E Ratio
-1.16
52-wk high
8.85
Low
3.06
Div yield
N/A
52-wk low
2.15
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 2:43 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:48 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 4:02 pm
Portfolio Pulse from Benzinga Insights
April 04, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 11:54 am
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 3:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.